Skip to main content

Best Manuscript Award 2021 for MedUni Vienna study

"Circulation Research", the official journal of the American Heart Association, honours team from Division of Nephrology and Dialysis
All News
Copyright: Hospital man/Shutterstock

(Vienna, 19 November 2021) A research team from the Division of Nephrology and Dialysis (Department of Medicine III of MedUni Vienna and Vienna General Hospital) led by Katharina Dörr and Rainer Oberbauer has been awarded the Best Manuscript Award 2021 for a study published in the prestigious journal Circulation Research. The award ceremony will be held on 26 January 2022.

According to the journal's editors, the article, "Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis", meets high standards of scientific excellence in terms of novelty, impact, and methodology; it was widely read online after publication and is one of the best papers published in Circulation Research in 2021 (impact factor 17.4).

Patients with chronic renal impairment often develop a thickening of the heart muscle, known as left ventricular hypertrophy. This is particularly pronounced in late-stage renal failure patients, i.e. those who require renal replacement therapy such as haemodialysis. The danger of this thickening of the heart muscle lies in a significantly increased risk of acute cardiovascular diseases such as sudden cardiac death. Patients on haemodialysis have several risk factors for the development of such myocardial thickening. One of these is an increase in so-called fibroblast growth factor 23 (FGF23), a protein that increases as kidney function deteriorates. However, FGF23 levels can be increased or decreased through the use of drugs.

The study was conducted at the Division of Nephrology and Dialysis within the Department of Medicine III of MedUni Vienna and Vienna General Hospital between 2017 and 2019 by Katharina Dörr from Rainer Oberbauer's research group. Approximately 850 million people worldwide suffer from chronic kidney disease. In Western countries, around 10% of the adult population has chronic kidney damage, primarily caused by diabetes and hypertension. Globally, approximately 2.4 million people a year die from the sequelae of chronic kidney disease. Most deaths have a cardiovascular cause.

Service: Circulation Research
“Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis”. Katharina Dörr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Thomas Prikoszovich, Rodrig Marculescu, Dietrich Beitzke, Alice Wielandner, Reinhold G Erben and Rainer Oberbauer. LINK: doi.org/10.1161/CIRCRESAHA.120.318556.